Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03578432 · ClinicalTrials.gov registry record · Early Phase 1
Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy
A Early Phase 1 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT03578432 is a Early Phase 1 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 2 participants.
The verdict
NCT03578432, a Early Phase 1 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This early phase 1 trial studies the use of everolimus in restoring salivary gland function in participants with locally advanced head and neck cancer after concurrent chemoradiation or radiation therapy alone.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Survey Administration
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-05-04 |
| Est. Completion | 2019-11-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03578432
The ClinicalTrials.gov registry entry for NCT03578432 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03578432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03578432 about?
NCT03578432 is a clinical study titled "Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy". This early phase 1 trial studies the use of everolimus in restoring salivary gland function in participants with locally advanced head and neck cancer after concurrent chemoradiation or radiation therapy alone.
What is the current status of trial NCT03578432?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2018-05-04. Estimated completion is 2019-11-15.
What interventions are being tested in trial NCT03578432?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Survey Administration (OTHER), Everolimus (DRUG).
Who is sponsoring clinical trial NCT03578432?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.